LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Charles River Laboratories International Inc

Geschlossen

BrancheGesundheitswesen

184.59 5.47

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

181.52

Max

185.77

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.9M

56M

Verkäufe

-27M

1B

KGV

Branchendurchschnitt

592.3

80.03

EPS

2.43

Gewinnspanne

5.529

Angestellte

18,700

EBITDA

-23M

198M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+10.28% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-136M

8.7B

Vorheriger Eröffnungskurs

179.12

Vorheriger Schlusskurs

184.59

Nachrichtenstimmung

By Acuity

15%

85%

20 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Charles River Laboratories International Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Dez. 2025, 23:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. Dez. 2025, 23:14 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. Dez. 2025, 22:01 UTC

Wichtige Markttreiber

Costco Wholesale Reports Higher Monthly Sales

3. Dez. 2025, 21:38 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. Dez. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. Dez. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. Dez. 2025, 23:10 UTC

Ergebnisse

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. Dez. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. Dez. 2025, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5M

3. Dez. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. Dez. 2025, 22:20 UTC

Ergebnisse

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. Dez. 2025, 22:19 UTC

Ergebnisse

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. Dez. 2025, 22:17 UTC

Ergebnisse

Salesforce Working to Add Voice to Agentforce, CEO Says

3. Dez. 2025, 22:16 UTC

Ergebnisse

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. Dez. 2025, 22:15 UTC

Ergebnisse

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. Dez. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. Dez. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Dez. 2025, 21:49 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:23 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. Dez. 2025, 21:19 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:06 UTC

Ergebnisse

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. Dez. 2025, 21:03 UTC

Ergebnisse

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer-Vergleich

Kursveränderung

Charles River Laboratories International Inc Prognose

Kursziel

By TipRanks

10.28% Vorteil

12-Monats-Prognose

Durchschnitt 192.73 USD  10.28%

Hoch 225 USD

Tief 165 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Charles River Laboratories International Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

12 ratings

7

Buy

5

Halten

0

Sell

Technischer Score

By Trading Central

117.16 / 144.77Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

20 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat